SoftOx Solutions AS (OSL:SOFTX)

Orchard Therapeutics Cash Flow Statement

Financials in millions NOK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-19.65	-42.94	-39.45	-71.14	-65.4	-37.41
Depreciation & Amortization	4.37	5.37	7.48	3.9	3.93	2.7
Other Operating Activities	-7.06	-7.51	-2.63	-22.56	-21.04	-12.31
Change in Accounts Receivable	0.94	0.94	6.84	0.88	0.29	-3.12
Change in Inventory	-	-	-	0.2	2.77	-2.97
Change in Other Net Operating Assets	53.07	76.71	28.52	2.78	6.89	-7.29
Operating Cash Flow	31.68	32.56	0.76	-85.94	-72.56	-60.39
Operating Cash Flow Growth	-	4203.12%	-	-	-	-
Capital Expenditures	-18.48	-19.83	-7.61	-4.85	-4.6	-7.67
Investing Cash Flow	-7.67	-19.83	-7.61	-4.85	-4.6	-7.67
Issuance of Common Stock	41.87	35.74	3.08	-	89.02	27.13
Other Financing Activities	-46.11	-45.61	4.52	40.71	10.32	-0.27
Financing Cash Flow	-4.24	-9.86	7.6	40.71	99.34	26.86
Miscellaneous Cash Flow Adjustments	-0	-0	-0	-	0	-
Net Cash Flow	19.77	2.86	0.75	-50.08	22.18	-41.19
Free Cash Flow	13.19	12.73	-6.85	-90.79	-77.16	-68.06
Free Cash Flow Margin	141.65%	160.80%	-98.17%	-1276.30%	-976.50%	-691.70%
Free Cash Flow Per Share	-	0.01	-0.64	-8.78	-7.46	-8.17
Levered Free Cash Flow	-73.91	-62.72	9.25	-55.4	-44.58	-50.62
Unlevered Free Cash Flow	-73.91	-57.14	14.83	-54	-44.53	-50.62
Change in Net Working Capital	46.03	22.39	-35.36	-3.87	-9.95	13.56

Updated Nov 27, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.